<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Rospo G</submitter><funding>AIRC under IG 2018</funding><funding>International Accelerator Award, ACRCelerate</funding><funding>Fondazione AIRC under 5 per Mille 2018</funding><funding>Cancer Research UK</funding><funding>European Research Council</funding><funding>AIRC MFAG 2020</funding><funding>IMI PERSIST-SEQ</funding><funding>AIRC 5x1000</funding><pagination>15</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10797964</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>16(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Immunotherapy based on checkpoint inhibitors is highly effective in mismatch repair deficient (MMRd) colorectal cancer (CRC). These tumors carry a high number of mutations, which are predicted to translate into a wide array of neoepitopes; however, a systematic classification of the neoantigen repertoire in MMRd CRC is lacking. Mass spectrometry peptidomics has demonstrated the existence of MHC class I associated peptides (MAPs) originating from non-coding DNA regions. Based on these premises we investigated DNA genomic regions responsible for generating MMRd-induced peptides.&lt;h4>Methods&lt;/h4>We exploited mouse CRC models in which the MMR gene Mlh1 was genetically inactivated. Isogenic cell lines CT26 Mlh1&lt;sup>+/+&lt;/sup> and Mlh1&lt;sup>-/-&lt;/sup> were inoculated in immunocomp</pubmed_abstract><journal>Genome medicine</journal><pubmed_title>Non-canonical antigens are the largest fraction of peptides presented by MHC class I in mismatch repair deficient murine colorectal cancer.</pubmed_title><pmcid>PMC10797964</pmcid><funding_grant_id>21763</funding_grant_id><funding_grant_id>22737</funding_grant_id><funding_grant_id>A28223</funding_grant_id><funding_grant_id>contract n. 101007937</funding_grant_id><funding_grant_id>22795</funding_grant_id><funding_grant_id>GEACC18004TAB</funding_grant_id><funding_grant_id>ID. 21923 project</funding_grant_id><funding_grant_id>A26825</funding_grant_id><funding_grant_id>Grant-ID 24604</funding_grant_id><funding_grant_id>Cancer Research UK (A26825 and A28223), FC AECC (GEACC18004TAB), and AIRC (22795)</funding_grant_id><funding_grant_id>ID. 21091 program</funding_grant_id><funding_grant_id>101020342</funding_grant_id><funding_grant_id>grant agreement no.101020342</funding_grant_id><pubmed_authors>Bartolini A</pubmed_authors><pubmed_authors>Germano G</pubmed_authors><pubmed_authors>Bachi A</pubmed_authors><pubmed_authors>Matafora V</pubmed_authors><pubmed_authors>Mondino A</pubmed_authors><pubmed_authors>Bardelli A</pubmed_authors><pubmed_authors>Lamba S</pubmed_authors><pubmed_authors>Chila R</pubmed_authors><pubmed_authors>Basso V</pubmed_authors><pubmed_authors>Di Nicolantonio F</pubmed_authors><pubmed_authors>Rospo G</pubmed_authors></additional><is_claimable>false</is_claimable><name>Non-canonical antigens are the largest fraction of peptides presented by MHC class I in mismatch repair deficient murine colorectal cancer.</name><description>&lt;h4>Background&lt;/h4>Immunotherapy based on checkpoint inhibitors is highly effective in mismatch repair deficient (MMRd) colorectal cancer (CRC). These tumors carry a high number of mutations, which are predicted to translate into a wide array of neoepitopes; however, a systematic classification of the neoantigen repertoire in MMRd CRC is lacking. Mass spectrometry peptidomics has demonstrated the existence of MHC class I associated peptides (MAPs) originating from non-coding DNA regions. Based on these premises we investigated DNA genomic regions responsible for generating MMRd-induced peptides.&lt;h4>Methods&lt;/h4>We exploited mouse CRC models in which the MMR gene Mlh1 was genetically inactivated. Isogenic cell lines CT26 Mlh1&lt;sup>+/+&lt;/sup> and Mlh1&lt;sup>-/-&lt;/sup> were inoculated in immunocomp</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Jan</publication><modification>2026-07-15T04:47:20.356Z</modification><creation>2025-04-04T19:22:14.289Z</creation></dates><accession>S-EPMC10797964</accession><cross_references><pubmed>38243308</pubmed><doi>10.1186/s13073-023-01275-3</doi></cross_references></HashMap>